BioSig Tech. (BSGM) & Electrophysiology Sector - BioSig Issues Shareholder Update to Highlight Recent Achievements and Ongoing Develop - BioSig Tech. (BSGM) & Electrophysiology Sector - InvestorVillage


BioSig Tech. (BSGM) & Electrophysiology Sector (related stock BSGM)
This is a semi-private group. You are free to browse messages, but you must be a member of this group to post messages. Join This Group

Group: BioSig Tech. (BSGM) & Electrophysiology Sector   /  Message Board  /  Read Message

 
 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  2395 of 2401  at  1/19/2023 8:52:27 AM  by

ZombieInvestor


BioSig Issues Shareholder Update to Highlight Recent Achievements and Ongoing Develop

On January 10, 2023, we announced that Bellin Health entered into an agreement to acquire a PURE EPô System. Through a formal evaluation, Bellin reported that clear cardiac signals positively impacted procedural efficiency resulting in cost savings per procedure.

Over 3,000 procedures have been performed using the PURE EPô System with more than 80 physicians at 21 hospitals across the United States.

The PURE EPô System was featured in an abstract presentation at the 15th Asia Pacific Heart Rhythm Society (APHRS) Scientific Session in Singapore. Results from the randomized study revealed the PURE EPô Systemís potential to promote shorter procedural times and higher cost savings during catheter ablation procedures.

BioSigís PURE EPô System was highlighted in a peer-reviewed case report by the Journal of Atrial Fibrillation & Electrophysiology (JAFIB-EP). This clinical abstract detailed the value of PURE EPô and its groundbreaking High Frequency Algorithm (HFA) during pulmonary vein isolation.

A Master Research Agreement was signed with the Cleveland Clinic to explore expanded applications for its digital signal processing technology.

A purchase agreement was signed with San Antonio Methodist Hospital.

Launched PURE EPô software Version 6 with ACCUVIZô Module highlighting the proprietary High Frequency Algorithm (HFA), a novel feature that identifies the key frequency components of cardiac data that can be difficult to identify within the traditional waveform presentation.

Cleveland Clinic, a leading Medical Center of Excellence, agreed to evaluate the PURE EP System, and a short time later requested a second system for evaluation.

A purchase agreement was signed with Kansas City Heart Rhythm Institute at Overland Park Regional Medical Center.

The PURE EPô System was featured at numerous conferences including Kansas City Heart Rhythm Symposium 2022, the 17th Edition Venice Arrhythmias 2022 Congress, and EPLive 2022.

https://finance.yahoo.com/news/biosig-issues-shareholder-highlight-recent-133000372.html


     e-mail to a friend      printer-friendly     add to library      
|  
Recs: 9  
   Views: 0 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board




Financial Market Data provided by
.
Loading...